(go to content)

Castellano | Euskara | Français | English

 Imagen decorativa
DTB: Vol 24, No 3

Content tools

Share it

  • Meneame
  • Delicious
  • Twitter
  • Google
  • Facebook

The EMPA-REG OUTCOME trial (empagliflozin). A critical appraisal. The power of truth, the truth of power

There is no solid evidence supporting the claims of superiority of empagliflozin over placebo for the prevention of macrovascular complications in diabetic patients with cardiovascular disease. The limitations of the EMPA-REG OUTCOME trial should be appropriately addressed before the drug’s indications are extended. Also, a confirmatory trial should be conducted to verify the results of the first study.


  • Luis Carlos Saiz. Pharmacist. Pharmacotherapy Research Coordinator Navarre Health Service. Spain
Enviar comentario

You can send us a comment or suggestion and we will respond to most frequently asked questions

Competing interests (complete this field only if you have competing interests)






Government of Navarre

Contact us | Accessibility | Legal notice | Site map